Context-restricted PD-(L)1 checkpoint agonism by CTLA4-Ig therapies inhibits T cell activity.
Oxley EP, Kershaw NJ, Louis C, Goodall KJ, Garwood MM, Jee Ho SM, Voo VTF, Park HY, Iaria J, Wong LLL, Lebenbaum AG, Wiranata S, Pang ES, Edwards ESJ, D'Silva DB, Hansen J, van Zelm MC, O'Keeffe M, Hogarth PM, Haynes NM, Huntington ND, Wicks IP, Dickins RA
Immune Disease + Cancer
Streamlining documentation in patient electronic medical records: An example of chlamydia consultation shortcuts.
Goller JL, Bittleston H, Munari S, McNamee K, Bateson D, Sanci L, Temple-Smith M, Hocking JS, Coombe J
Sexual + Reproductive Health
Stellabody®: A novel hexamer-promoting mutation for improved IgG potency
Whitehead CA, Wines BD, Davies AM, McDonnell JM, Trist HM, Esparon SE, Hogarth PM
Immune Disease + Cancer
Utilising integrated bio-behavioural surveillance (IBBS) to investigate declining hepatitis C antibody prevalence among people who inject drugs in the Australian Needle and Syringe Program Survey.
Maher L, Wand H, Heard S, Starr M, Zolala F, Kemp R, Cunningham P, Drummer H, Hellard M, Kaldor J, Dore G
Hepatitis C Injecting Drug Use